Suppression of tumourigenicity, and induction of differentiation of the canine mammary tumour cell line MCM-B2 by sodium phenylacetate.
The authors evaluated the cell growth inhibition, reduction of tumourigenicity, and differentiation-inducing effects of sodium phenylacetate (NaPA) on a canine mammary tumour cell line. Treatment of the canine mammary tumour cell line (MCM-B2) with NaPA lead to the arrest of cell growth. Sodium phenylacetate induced changes in the cells to non-malignant characteristics, as indicated by a reduction of colony formation in semi-solid agar and a decrease in tumour formation in athymic mice. Moreover, NaPA induced morphological changes from a spindle-shaped to an epithelial-like appearance, and significant accumulation of lipid droplets in the cytoplasm. Immunohistochemically, these treated cells reacted clearly with the antibody for keratin/cytokeratin. Sodium phenylacetate treatment increased the expression of the milk-specific genes alpha-lactalbumin and beta-casein. The results of this study warrant an evaluation of NaPA in a clinical trial to establish its possible value as adjunctive treatment of malignant canine mammary tumours.
Watanabe
M
M
Department of Veterinary Pathology, Faculty of Agriculture, Miyazaki University, 889-2155, Miyazaki, Japan.
Sugano
S
S
Imai
J
J
Yoshida
K
K
Onodera
R
R
Amin
M R
MR
Uchida
K
K
Yamaguchi
R
R
Tateyama
S
S
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D004283:Dog Diseases / Q000473:pathology*; D004285:Dogs; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000473:pathology*; D010648:Phenylacetates / Q000494:pharmacology*; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000662:veterinary; D014407:Tumor Cells, Cultured
D000964:Antimetabolites, Antineoplastic; D010648:Phenylacetates; C025136:phenylacetic acid